Profile data is unavailable for this security.
About the company
Lyka Labs Limited is an India-based company that is engaged in the business of pharmaceutical and related activities, including research. The Company is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The Company manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
- Revenue in INR (TTM)1.06bn
- Net income in INR-35.60m
- Incorporated1976
- Employees713.00
- LocationLyka Labs Ltd101 - Shiv Shakti Industrial EstateAndheri Kurla Road, Andheri (East)MUMBAI 400036IndiaIND
- Phone+91 2 266112200
- Fax+91 2 266112248
- Websitehttp://www.lykalabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Drugs and Chemicals Ltd | 973.13m | 142.29m | 3.38bn | 105.00 | 23.77 | -- | 19.19 | 3.48 | 11.56 | 11.56 | 79.09 | -- | -- | -- | -- | 9,267,876.00 | -- | 11.67 | -- | 14.69 | 63.65 | 43.30 | 14.62 | 11.82 | -- | 210.51 | -- | -- | 27.54 | 17.71 | 23.02 | 49.94 | 64.23 | -- |
| Medico Remedies Ltd | 1.32bn | 69.58m | 3.78bn | -- | 54.71 | -- | 38.47 | 2.87 | 0.8326 | 0.8326 | 15.75 | -- | -- | -- | -- | -- | -- | 4.76 | -- | 10.00 | 24.15 | 24.40 | 5.29 | 3.14 | -- | 11.07 | -- | -- | 16.04 | 18.14 | 48.09 | 42.78 | 52.68 | -- |
| Lyka Labs Ltd | 1.06bn | -35.60m | 4.24bn | 713.00 | -- | -- | 43.07 | 4.01 | -1.23 | -1.23 | 33.69 | -- | -- | -- | -- | -- | -- | -5.48 | -- | -9.31 | 61.37 | 59.75 | -3.34 | -10.63 | -- | 0.5422 | -- | -- | -52.05 | 8.95 | -133.88 | -- | 17.78 | -- |
| Venus Remedies Ltd. | 5.62bn | 290.26m | 4.26bn | 998.00 | 14.68 | -- | 7.37 | 0.759 | 21.73 | 21.73 | 420.31 | -- | -- | -- | -- | 5,630,556.00 | -- | 2.84 | -- | 3.84 | 42.76 | 39.68 | 5.17 | 3.83 | -- | 559.36 | -- | -- | -7.21 | 8.33 | -34.77 | -- | -10.05 | -- |
| Wanbury Ltd | 5.69bn | 233.39m | 4.89bn | 1.58k | 20.95 | -- | 13.51 | 0.8583 | 7.12 | 7.12 | 173.80 | -- | -- | -- | -- | 3,598,099.00 | -- | 6.56 | -- | -- | 46.15 | 43.92 | 4.10 | 4.54 | -- | 1.82 | -- | -- | -2.26 | 5.95 | -112.76 | -- | 34.73 | -- |
